AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30298070 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of 20-30% iron-saturated bovine lactoferrin (bLf) twice a day
Number of subjects: 198
Study 30298070 — intervention group
Group type: COMPARATOR
Intervention: 329.7 mg of ferrous sulfate once a day (control)
Number of subjects: 198
Study 30298340 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosignature analysis using a 256-peptide signature derived from serum antibodies.
Number of subjects: 25
Study 30298340 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosignature analysis using a 654-peptide signature derived from serum antibodies.
Number of subjects: 25
Study 30298340 — intervention group
Group type: COMPARATOR
Intervention: Testing of the immunosignature in international data sets.
Number of subjects: 25
Study 30298381 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy (RT) at a total dose of 20 Gy delivered BID in two consecutive days.
Number of subjects: 54
Study 30298444 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (1.5 pmol/kg/min dissolved in 500 ml of 0.9% saline)
Number of subjects: 14
Study 30298444 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 ml of 0.9% saline)
Number of subjects: 14
Study 30298462 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal prompt for facial expression production
Number of subjects: 0
Study 30298568 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obese nonalcoholic fatty liver disease
Number of subjects: 664
Study 30298568 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obese nonalcoholic steatohepatitis
Number of subjects: 664
Study 30298568 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of nonalcoholic steatohepatitis in non-obese subjects
Number of subjects: 664
Study 30298568 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of significant fibrosis in non-obese subjects
Number of subjects: 664
Study 30298568 — intervention group
Group type: EXPERIMENTAL
Intervention: Sagittal abdominal diameter
Number of subjects: 664
Study 30298593 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expandable sirolimus-eluting stents (SES)
Number of subjects: 151
Study 30298593 — intervention group
Group type: COMPARATOR
Intervention: Second-generation drug-eluting stents (DES-II)
Number of subjects: 151
Study 30298796 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaemic child and overweight mother
Number of subjects: 437
Study 30298796 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaemic child and obese mother
Number of subjects: 437
Study 30298796 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurrence of anaemia in child and excess adiposity in mother
Number of subjects: 437
Study 30299161 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-PLS patients
Number of subjects: 13
Study 30299161 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with longstanding primary lateral sclerosis
Number of subjects: 13
Study 30299161 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-PLS patients (initial scans)
Number of subjects: 13
Study 30299161 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up scans in pre-PLS patients
Number of subjects: 13
Study 30299161 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 13
Study 30299161 — intervention group
Group type: COMPARATOR
Intervention: Patients with longstanding disease
Number of subjects: 13
Study 30299230 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous (iv) alteplase (0.6 mg/kg body weight)
Number of subjects: 0
Study 30299230 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensive blood pressure (BP) lowering (systolic target 130-140 mmHg)
Number of subjects: 0
Study 30300158 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlens system (light-driven contact hearing aid)
Number of subjects: 78
Study 30300264 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesopic testing at distances of 0.43°, 0.86°, 1.29°, 2.15°, and 3.01°
Number of subjects: 25
Study 30300264 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark-adapted cyan sensitivity
Number of subjects: 25
Study 30300751 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully-automatic segmentation framework for spinal cord and intramedullary MS lesions from MRI data.
Number of subjects: 1042
Study 30300751 — intervention group
Group type: COMPARATOR
Intervention: Conventional MRI data of MS and non-MS cases.
Number of subjects: 1042
Study 30301763 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (18-25 years)
Number of subjects: 49603
Study 30301763 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (18-39 years)
Number of subjects: 49603
Study 30301763 — intervention group
Group type: EXPERIMENTAL
Intervention: Having postsecondary education
Number of subjects: 49603
Study 30301763 — intervention group
Group type: EXPERIMENTAL
Intervention: Being a student
Number of subjects: 49603
Study 30301763 — intervention group
Group type: EXPERIMENTAL
Intervention: Living alone, low education, low physical activity, being a homemaker/disabled/unemployed/retired, a manual worker or a former/current smoker
Number of subjects: 49603
Study 30302121 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 37
Study 30302121 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 37
Study 30302374 — intervention group
Group type: EXPERIMENTAL
Intervention: Linked color imaging
Number of subjects: 0
Study 30302599 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily with mFOLFOX-6 + bevacizumab
Number of subjects: 35
Study 30302599 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 7.5 mg daily with mFOLFOX-6 + bevacizumab (recommended phase II dose)
Number of subjects: 35
Study 30302762 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPS (noninvasive programmed ventricular stimulation)
Number of subjects: 105
Study 30304477 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing Disability in Alzheimer's Disease-NorthWest (RDAD-NW) intervention
Number of subjects: 255
Study 30304513 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 3493
Study 30304652 — intervention group
Group type: EXPERIMENTAL
Intervention: ex vivo-expanded, partially HLA-matched, third-party-produced, cryopreserved BK virus-specific T cells
Number of subjects: 3
Study 30305055 — intervention group
Group type: EXPERIMENTAL
Intervention: Obatoclax
Number of subjects: 0
Study 30305055 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAIL
Number of subjects: 0
Study 30305055 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of obatoclax and TRAIL
Number of subjects: 0
Study 30305055 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib
Number of subjects: 0
Study 30305103 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Emotion Regulation Individual Therapy for Adolescents (ERITA)
Number of subjects: 25
Study 30305103 — intervention group
Group type: EXPERIMENTAL
Intervention: Online therapist-guided parent program
Number of subjects: 25
Study 30305183 — intervention group
Group type: EXPERIMENTAL
Intervention: PlasmaBlade
Number of subjects: 20
Study 30305346 — intervention group
Group type: EXPERIMENTAL
Intervention: Control-IQ Technology (Tandem Diabetes Care)
Number of subjects: 5
Study 30305449 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal rituximab (25 mg with a 1-week interval)
Number of subjects: 23
Study 30305890 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-Directed Fluid Therapy (GDFT)
Number of subjects: 401
Study 30305890 — intervention group
Group type: COMPARATOR
Intervention: Standard intraoperative fluid management (Control)
Number of subjects: 401
Study 30305961 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich fruit and vegetable liquid supplement (FVS, AMPED NOx, Isagenix International LLC)
Number of subjects: 45
Study 30305961 — intervention group
Group type: COMPARATOR
Intervention: Juice low in nitrates (prune juice, PRU)
Number of subjects: 45
Study 30305980 — intervention group
Group type: EXPERIMENTAL
Intervention: BRNS
Number of subjects: 50
Study 30305980 — intervention group
Group type: EXPERIMENTAL
Intervention: Butterfly strip
Number of subjects: 50
Study 30305980 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype strips
Number of subjects: 50
Study 30305980 — intervention group
Group type: EXPERIMENTAL
Intervention: All strips (BRNS, Butterfly, Prototype)
Number of subjects: 50
Study 30305980 — intervention group
Group type: EXPERIMENTAL
Intervention: All strips (BRNS, Butterfly)
Number of subjects: 50
Study 30306125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hu08BBz CAR T cells
Number of subjects: 0
Study 30306125 — intervention group
Group type: EXPERIMENTAL
Intervention: Hu13Rα2 CAR T cells with CTLA-4 blockade
Number of subjects: 0
Study 30306125 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFRvIII CAR T cells with PD-1 and TIM-3 blockade
Number of subjects: 0
Study 30306125 — intervention group
Group type: COMPARATOR
Intervention: Hu07BBz CAR T cells
Number of subjects: 0
Study 30306144 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive complementary feeding intervention
Number of subjects: 100
Study 30306144 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 30306221 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hepatocyte growth factor (HGF) in AS patients
Number of subjects: 204
Study 30306221 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum matrix metalloproteinase-3 (MMP-3) in AS patients
Number of subjects: 204
Study 30306221 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum vascular endothelial growth factor (VEGF) in AS patients
Number of subjects: 204
Study 30306221 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple linear regression analysis of serum HGF
Number of subjects: 204
Study 30306221 — intervention group
Group type: COMPARATOR
Intervention: Comparison of serum HGF levels between male AS patients and HC
Number of subjects: 204
Study 30306423 — intervention group
Group type: EXPERIMENTAL
Intervention: Copenhagen Baby Heart Study (CBHS) intervention including echocardiographic examination, electrocardiography, and post-ductal pulse oximetry shortly after birth.
Number of subjects: 25000
Study 30306423 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a specialist or hospital admission for infants diagnosed with significant CHD based on severity.
Number of subjects: 25000
Study 30306534 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing loss in survivors of CNS tumours
Number of subjects: 700
Study 30306534 — intervention group
Group type: COMPARATOR
Intervention: Hearing loss in survivors of other cancers
Number of subjects: 700
Study 30306834 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized community-based physical activity intervention (16 weeks)
Number of subjects: 46
Study 30307350 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL of 20% intravenous lipid emulsion
Number of subjects: 40
Study 30307350 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid emulsion
Number of subjects: 40
Study 30307465 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbrella biomarker-driven study
Number of subjects: 0
Study 30307609 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally tailored clinical guidelines
Number of subjects: 188
Study 30307663 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil
Number of subjects: 30
Study 30307663 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 30
Study 30308224 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation at 20 months of age
Number of subjects: 723
Study 30308224 — intervention group
Group type: EXPERIMENTAL
Intervention: Restriction for health at 20 months of age
Number of subjects: 723
Study 30308224 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure to eat at 20 months of age
Number of subjects: 723
Study 30308484 — intervention group
Group type: EXPERIMENTAL
Intervention: Joining parents' bed every night
Number of subjects: 635
Study 30308484 — intervention group
Group type: EXPERIMENTAL
Intervention: Joining parents' bed rarely
Number of subjects: 635
Study 30308484 — intervention group
Group type: COMPARATOR
Intervention: Not joining parents' bed
Number of subjects: 635
Study 30309321 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenem-resistant strains (n=43)
Number of subjects: 92
Study 30309321 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidrug-resistant strains (n=11)
Number of subjects: 92
Study 30309321 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenem- and multidrug-resistant strains (n=38)
Number of subjects: 92
Study 30309321 — intervention group
Group type: EXPERIMENTAL
Intervention: Strains with clinically relevant beta-lactamases (OXA-101, OXA-2, GES-5)
Number of subjects: 92
Study 30309321 — intervention group
Group type: EXPERIMENTAL
Intervention: Strains with aminoglycoside modifying enzymes
Number of subjects: 92
Study 30309321 — intervention group
Group type: EXPERIMENTAL
Intervention: Strains with defective OprD
Number of subjects: 92
Study 30309342 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA) and laboratory evaluations including serum creatinine and albumin-to-creatinine ratio
Number of subjects: 2450
Study 30309342 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate telephone follow-up at 6 and 18 months
Number of subjects: 2450
Study 30309472 — intervention group
Group type: EXPERIMENTAL
Intervention: Home fetal heart rate monitoring (FHRM) twice daily with a Doppler monitor and weekly or biweekly fetal echocardiograms.
Number of subjects: 315
Study 30309472 — intervention group
Group type: EXPERIMENTAL
Intervention: Home fetal heart rate monitoring (FHRM) and echocardiograms discontinued after 26 weeks.
Number of subjects: 315
Study 30309472 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal echocardiograms performed as part of the monitoring protocol.
Number of subjects: 315
Study 30309758 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1, then day 1 of subsequent cycles)
Number of subjects: 1202
Study 30309758 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (375 mg/m2)
Number of subjects: 1202
Study 30309758 — intervention group
Group type: EXPERIMENTAL
Intervention: PET complete responders (IHP 2007 criteria)
Number of subjects: 1202
Study 30309758 — intervention group
Group type: COMPARATOR
Intervention: Non-complete responders (IHP 2007 criteria)
Number of subjects: 1202
Study 30309758 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete metabolic responders (Lugano 2014 criteria)
Number of subjects: 1202
Study 30309758 — intervention group
Group type: COMPARATOR
Intervention: Non-complete metabolic responders (Lugano 2014 criteria)
Number of subjects: 1202
Study 30309854 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30309993 — intervention group
Group type: EXPERIMENTAL
Intervention: Own brand cigarette
Number of subjects: 25
Study 30309993 — intervention group
Group type: COMPARATOR
Intervention: Flavoured cigar (apple, cream, original, wine)
Number of subjects: 25
Study 30310267 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (AF group)
Number of subjects: 30
Study 30310267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab with photodynamic therapy (PDT group)
Number of subjects: 30
Study 30310267 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab (control group)
Number of subjects: 30
Study 30310267 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from ranibizumab to aflibercept
Number of subjects: 30
Study 30311073 — intervention group
Group type: EXPERIMENTAL
Intervention: HUMAN (manually-adapted target controlled infusion protocol)
Number of subjects: 36
Study 30311073 — intervention group
Group type: EXPERIMENTAL
Intervention: EPSAC (computer-controlled predictive control strategy)
Number of subjects: 36
Study 30311073 — intervention group
Group type: EXPERIMENTAL
Intervention: BAYES (computer-controlled Bayesian rule-based optimized control strategy)
Number of subjects: 36
Study 30311073 — intervention group
Group type: COMPARATOR
Intervention: HUMAN
Number of subjects: 36
Study 30311073 — intervention group
Group type: COMPARATOR
Intervention: EPSAC
Number of subjects: 36
Study 30311073 — intervention group
Group type: COMPARATOR
Intervention: BAYES
Number of subjects: 36
Study 30311792 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass spectrometry techniques to detect Treponema pallidum antigens in urine
Number of subjects: 60
Study 30311792 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 60
Study 30311822 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one meeting with a twelve-step program volunteer
Number of subjects: 72
Study 30312482 — intervention group
Group type: EXPERIMENTAL
Intervention: CELLEX ECP instrument
Number of subjects: 0
Study 30312482 — intervention group
Group type: COMPARATOR
Intervention: UVAR XTS ECP instrument
Number of subjects: 0
Study 30312541 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-based immunosuppression
Number of subjects: 111
Study 30312541 — intervention group
Group type: COMPARATOR
Intervention: Standard immunosuppression
Number of subjects: 111
Study 30312717 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage low-dose-rate (LDR) brachytherapy
Number of subjects: 92
Study 30314417 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard behavioral treatment with additional one-on-one self-efficacy enhancement sessions
Number of subjects: 120
Study 30314417 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral treatment
Number of subjects: 120
Study 30314835 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable scaffold (BRS) implantation
Number of subjects: 505
Study 30314962 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based exercise intervention (8 weeks, individualized, supervised)
Number of subjects: 20
Study 30314962 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based exercise intervention
Number of subjects: 20
Study 30314962 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (control group)
Number of subjects: 20
Study 30315349 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride (HDC)
Number of subjects: 3
Study 30316443 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate prediction model for diagnosing adenomyosis
Number of subjects: 100
Study 30316443 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of myometrial cysts
Number of subjects: 100
Study 30316443 — intervention group
Group type: EXPERIMENTAL
Intervention: Fan-shaped echo
Number of subjects: 100
Study 30316443 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperechoic islets
Number of subjects: 100
Study 30316443 — intervention group
Group type: EXPERIMENTAL
Intervention: Globular uterus
Number of subjects: 100
Study 30316443 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal uterine shape
Number of subjects: 100
Study 30316443 — intervention group
Group type: EXPERIMENTAL
Intervention: Thickest/thinnest ratio for uterine wall
Number of subjects: 100
Study 30316443 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum width of the junctional zone in sagittal plane
Number of subjects: 100
Study 30316443 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular appearance of junctional zone
Number of subjects: 100
Study 30316443 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade of dysmenorrhea measured on a verbal numerical rating scale
Number of subjects: 100
Study 30316782 — intervention group
Group type: EXPERIMENTAL
Intervention: Dot app (Dynamic Optimal Timing)
Number of subjects: 718
Study 30316827 — intervention group
Group type: EXPERIMENTAL
Intervention: NHT plus WPRT
Number of subjects: 1322
Study 30316827 — intervention group
Group type: EXPERIMENTAL
Intervention: NHT plus PORT
Number of subjects: 1322
Study 30316827 — intervention group
Group type: EXPERIMENTAL
Intervention: WPRT plus AHT
Number of subjects: 1322
Study 30316827 — intervention group
Group type: EXPERIMENTAL
Intervention: PORT plus AHT
Number of subjects: 1322
Study 30316935 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 1806
Study 30316935 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 1806
Study 30316935 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-measured VAT
Number of subjects: 1806
Study 30316935 — intervention group
Group type: EXPERIMENTAL
Intervention: None of the adiposity measures
Number of subjects: 1806
Study 30317494 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD patients (n=46)
Number of subjects: 46
Study 30317494 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n=20)
Number of subjects: 46
Study 30317671 — intervention group
Group type: EXPERIMENTAL
Intervention: ixekizumab 160 mg at Week 0, 80 mg every 2 weeks through Week 12, and 80 mg every 4 weeks thereafter up to Week 244
Number of subjects: 13
Study 30318513 — intervention group
Group type: EXPERIMENTAL
Intervention: ARQ 761 (β-lapachone analogue) at a maximum tolerated dose of 390 mg/m, administered on three schedules (weekly, every other week, 2/3 weeks)
Number of subjects: 42
Study 30318513 — intervention group
Group type: EXPERIMENTAL
Intervention: ARQ 761 (β-lapachone analogue)
Number of subjects: 42
Study 30318516 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + hypofractionated radiotherapy (HFRT)
Number of subjects: 24
Study 30318646 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) dose
Number of subjects: 1472
Study 30318646 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) trough
Number of subjects: 1472
Study 30318646 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 loss-of-function alleles
Number of subjects: 1472
Study 30318722 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium chloride 1 mM
Number of subjects: 205
Study 30319397 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention for 16 weeks
Number of subjects: 0
Study 30319400 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic four-drug regimen
Number of subjects: 0
Study 30319400 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30319644 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Number of subjects: 8
Study 30319729 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonthermal Pulsed Ultrasound Treatment
Number of subjects: 0
Study 30319729 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0